Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Novartis
Covington
Argus Health
Dow
US Department of Justice
McKesson
Chinese Patent Office
Daiichi Sankyo
Fuji

Generated: August 19, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021842

« Back to Dashboard
NDA 021842 describes ACTOPLUS MET, which is a drug marketed by Takeda Pharms Usa and is included in two NDAs. It is available from four suppliers. There are thirteen patents protecting this drug and two Paragraph IV challenges. Additional details are available on the ACTOPLUS MET profile page.

The generic ingredient in ACTOPLUS MET is metformin hydrochloride; pioglitazone hydrochloride. There are forty-eight drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; pioglitazone hydrochloride profile page.

Summary for NDA: 021842

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:2
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 021842

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ACTOPLUS MET
metformin hydrochloride; pioglitazone hydrochloride
TABLET;ORAL 021842 NDA AUTHORIZED GENERIC Teva Pharmaceuticals USA 0093-5049 0093-5049-06 60 TABLET, FILM COATED in 1 BOTTLE (0093-5049-06)
ACTOPLUS MET
metformin hydrochloride; pioglitazone hydrochloride
TABLET;ORAL 021842 NDA AUTHORIZED GENERIC Teva Pharmaceuticals USA 0093-5049 0093-5049-86 180 TABLET, FILM COATED in 1 BOTTLE (0093-5049-86)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength500MG;EQ 15MG BASE
Approval Date:Aug 29, 2005TE:ABRLD:Yes
Patent:► SubscribePatent Expiration:Jan 22, 2027Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Feb 3, 2029Product Flag?YSubstance Flag?Delist Request?

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength850MG;EQ 15MG BASE
Approval Date:Aug 29, 2005TE:ABRLD:Yes
Patent:► SubscribePatent Expiration:Jan 22, 2027Product Flag?YSubstance Flag?Delist Request?

Expired Orange Book Patents for NDA: 021842



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
UBS
McKinsey
Deloitte
Teva
US Army
Mallinckrodt
Merck
Moodys
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot